{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:12:30Z","timestamp":1715386350402},"reference-count":22,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,3,31]]},"DOI":"10.1536\/ihj.22-496","type":"journal-article","created":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T22:10:44Z","timestamp":1674425444000},"page":"95-99","source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia"],"prefix":"10.1536","volume":"64","author":[{"given":"Tomonobu","family":"Yanase","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"},{"name":"Advanced Medical Center for Heart Failure, The University of Tokyo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Bujo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"},{"name":"Department of Therapeutic Strategy for Heart Failure, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuetsu","family":"Fukushi","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souichi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Aryal S, Katugaha SB, Cochrane A, <i>et al<\/i>. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transpl Infect Dis 2019; 21: e13166.","DOI":"10.1111\/tid.13166"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stoelben S, Arns W, Renders L, <i>et al<\/i>. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int 2014; 27: 77-86.","DOI":"10.1111\/tri.12225"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Schreiber A, H\u00e4rter G, Schubert A, Bunjes D, Mertens T, Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009; 10: 191-209.","DOI":"10.1517\/14656560802678138"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18: 233-46.","DOI":"10.1002\/rmv.574"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884-93.","DOI":"10.1128\/JVI.05265-11"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist 2019; 12: 1481-91.","DOI":"10.2147\/IDR.S180908"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Imlay HN, Kaul DR. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis 2021; 73: 156-60.","DOI":"10.1093\/cid\/ciaa1713"},{"key":"8","unstructured":"8. Billingham ME, Cary NR, Hammond ME, <i>et al<\/i>. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-93."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Stewart S, Winters GL, Fishbein MC, <i>et al<\/i>. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-20.","DOI":"10.1016\/j.healun.2005.03.019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Costanzo MR, Dipchand A, Starling R, <i>et al<\/i>. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-56.","DOI":"10.1016\/j.healun.2010.05.034"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Linder KA, Kovacs C, Mullane KM, <i>et al<\/i>. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transpl Infect Dis 2021; 23: e13687.","DOI":"10.1111\/tid.13687"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Turner N, Strand A, Grewal DS, <i>et al<\/i>. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. Antimicrob Agents Chemother 2019; 63.","DOI":"10.1128\/AAC.02337-18"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Veit T, Munker D, Barton J, <i>et al<\/i>. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study. Am J Transplant 2021; 21: 3449-55.","DOI":"10.1111\/ajt.16718"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hofmann E, Sidler D, Dahdal S, <i>et al<\/i>. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature. Transpl Infect Dis 2021; 23: e13515.","DOI":"10.1111\/tid.13515"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14: 633-41.","DOI":"10.1007\/s11908-012-0292-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Andrassy J, Hoffmann VS, Rentsch M, <i>et al<\/i>. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation 2012; 94: 1208-17.","DOI":"10.1097\/TP.0b013e3182708e56"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Eisen HJ, Kobashigawa J, Starling RC, <i>et al<\/i>. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13: 1203-16.","DOI":"10.1111\/ajt.12181"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Eisen HJ, Tuzcu EM, Dorent R, <i>et al<\/i>. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-58.","DOI":"10.1056\/NEJMoa022171"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest 2000; 118: 1792-800.","DOI":"10.1378\/chest.118.6.1792"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marty FM, Ljungman P, Chemaly RF, <i>et al<\/i>. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med 2017; 377: 2433-44.","DOI":"10.1056\/NEJMoa1706640"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Menzel K, Kothare P, McCrea JB, Chu X, Kropeit D. Absorption, Metabolism, Distribution, and Excretion of Letermovir. Curr Drug Metab 2021; 22: 784-94.","DOI":"10.2174\/1389200222666210223112826"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Avery RK, Alain S, Alexander BD, <i>et al<\/i>. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis 2022; 75: 690-701.","DOI":"10.1093\/cid\/ciab988"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/1\/64_22-496\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:05:33Z","timestamp":1715317533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/1\/64_22-496\/_article"}},"subtitle":["A Case Report and Review of Literature"],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-496","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"article-number":"22-496"}}